Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties-Reference-Cited by-同舟云学术

Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties

Published:2020-10-29 Issue:21 Volume:63 Page:12957-12977
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Soth Michael J.¹^ORCID,Le Kang¹,Di Francesco Maria Emilia¹,Hamilton Matthew M.¹,Liu Gang¹,Burke Jason P.¹,Carroll Chris L.¹,Kovacs Jeffrey J.²,Bardenhagen Jennifer P.¹,Bristow Christopher A.²,Cardozo Mario¹,Czako Barbara¹^ORCID,de Stanchina Elisa³,Feng Ningping²,Garvey Jill R.²,Gay Jason P.²,Do Mary K. Geck¹,Greer Jennifer²,Han Michelle¹,Harris Angela²,Herrera Zachary¹,Huang Sha¹,Giuliani Virginia²,Jiang Yongying¹,Johnson Sarah B.²,Johnson Troy A.¹,Kang Zhijun¹,Leonard Paul G.¹,Liu Zhen¹,McAfoos Timothy¹,Miller Meredith²,Morlacchi Pietro¹,Mullinax Robert A.²,Palmer Wylie S.¹,Pang Jihai¹,Rogers Norma¹,Rudin Charles M.⁴,Shepard Hannah E.¹,Spencer Nakia D.²,Theroff Jay¹,Wu Qi¹,Xu Alan¹,Yau Ju Anne¹,Draetta Giulio¹²,Toniatti Carlo²,Heffernan Timothy P.²,Jones Philip¹

Affiliation:

1. Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States

2. Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States

3. Antitumor Assessment Core Facility—Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States

4. Drunkenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York New York 10065, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01398

Reference50 articles.

1. Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions

2. Glutaminase regulation in cancer cells: a druggable chain of events

3. Glutamine and cancer: cell biology, physiology, and clinical opportunities